Britain and America have agreed to a significant commercial pact that will maintain no duties on British medicine exports entering the American market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has agreed to increase spending on medicines through the National Health Service (NHS). This commitment guarantees that import taxes on these key products will stay at zero for a period of the next three years.
This deal comes after previous warnings to dramatically increase duties on patented drug imports, with figures mentioned reaching double the cost.
"This agreement with the UK bolsters the global environment for new treatments and establishes much-needed fairness to transatlantic drug exports," a release said.
Trade Importance
Medicines constitute one of the the United Kingdom's biggest goods shipped to the United States, which is by far the biggest destination for large companies like GSK and AstraZeneca.
Export figures show that in the year prior to the third quarter, the UK sold drugs worth over eleven billion pounds to the US. This amount represented a significant portion of total UK exports in that span.
"This agreement safeguards work, boosts investment and sets the stage for the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary commented.
Key NHS Changes
The deal involves several specific commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it considers new therapies to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a goal to double overall NHS spending on drugs from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Refund Ceiling: The sum drug companies must pay back to the NHS to prevent overspending will be capped at fifteen percent. Last year, refunds exceeded twenty percent.
Industry Background
The deal follows a long-running row between the sector and the ministers over medicine costs and approval rates.
This friction were exacerbated by claims that US customers were charged a premium for the identical medicines than people in the other developed nations.
Over the last 18 months, several large pharmaceutical investments in the UK have been paused or scrapped, while multi-billion-dollar investments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS needed to invest a greater share on drugs, noting that its expenditure on drugs had declined as a proportion of its overall budget over the last ten years.
